News & Events : Press Releases
January 12, 2016
FORMA THERAPEUTICS ACHIEVES AN ADDITIONAL MAJOR OBJECTIVE IN COLLABORATION WITH CELGENE CORPORATION TO ADVANCE INNOVATIVE PROTEIN HOMEOSTASIS DRUGS
WATERTOWN, Mass. – January 12, 2016 – FORMA Therapeutics announced today that it has successfully met a third objective under its strategic collaboration agreement with Celgene Corporation, triggering an undisclosed payment from Celgene. In April 2013, FORMA and Celgene entered into a collaboration to discover, develop and commercialize drug candidates to regulate protein homeostasis targets. This collaboration enables Celgene to evaluate select target programs and lead compounds in protein homeostasis pathways during preclinical development.
John Hohneker, M.D., Head of Research and Development, FORMA Therapeutics said, “We have successfully identified another group of novel candidate compounds from our protein homeostasis programs with a compelling mechanism of action and direct clinical applications for patients with cancer. This success underscores the shared vision of Forma therapeutics and Celgene on the clinical promise of this class of targets that could be first in class.”
About Protein Homeostasis
Protein homeostasis, which is important in oncology, neurodegenerative and other disorders, involves a tightly regulated network of pathways controlling the biogenesis, folding, transport and degradation of proteins. Exploring the maintenance and regulation of such competing, yet integrated, biological pathways using a chemical biology approach should directly contribute to the understanding of diseases associated with excessive protein misfolding, aggregation and degradation.
FORMA Therapeutics' scientists are passionate about discovering and developing medicines that will make a difference in oncology and other genetically driven therapeutic areas. The company's drug discovery engine drives screening and structure-based approaches across broad families of targets involved in tumor metabolism, epigenetics, protein homeostasis and protein-protein interactions. Deep biological insight across targets is combined with the company's chemistry expertise and integrated with a world class network of academic investigators, clinical experts and corporate partners to rapidly direct the creation of high quality, innovative drug candidates.
FORMA is headquartered in Watertown, MA near the epicenter of the Cambridge Life Sciences cluster, with additional chemistry operations in Branford, CT. www.formatherapeutics.com
Join our conversation on Twitter @FORMAInc.
For FORMA Therapeutics
Kari Watson +1 781-235-3060
MacDougall Biomedical Communications